LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

7.1 -3.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.07

Max

7.16

Schlüsselkennzahlen

By Trading Economics

Einkommen

5.7M

-30M

Verkäufe

3.1M

34M

Gewinnspanne

-89.424

Angestellte

182

EBITDA

5.2M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+226.54% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

82M

765M

Vorheriger Eröffnungskurs

10.5

Vorheriger Schlusskurs

7.1

Nachrichtenstimmung

By Acuity

50%

50%

148 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Sept. 2025, 22:41 UTC

Wichtige Markttreiber

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12. Sept. 2025, 16:04 UTC

Wichtige Markttreiber

Upexi Shares Climb on Solana Gains

14. Sept. 2025, 23:48 UTC

Market Talk

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14. Sept. 2025, 23:41 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

14. Sept. 2025, 23:38 UTC

Market Talk

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Global Energy Roundup: Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14. Sept. 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Sept. 2025, 23:04 UTC

Market Talk

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13. Sept. 2025, 08:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Sept. 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

12. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Sept. 2025, 20:09 UTC

Ergebnisse

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12. Sept. 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. Sept. 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. Sept. 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12. Sept. 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12. Sept. 2025, 18:38 UTC

Market Talk
Ergebnisse

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12. Sept. 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12. Sept. 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12. Sept. 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12. Sept. 2025, 16:22 UTC

Ergebnisse

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12. Sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Sept. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12. Sept. 2025, 16:11 UTC

Ergebnisse

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12. Sept. 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12. Sept. 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12. Sept. 2025, 15:07 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

226.54% Vorteil

12-Monats-Prognose

Durchschnitt 23.25 USD  226.54%

Hoch 34 USD

Tief 16 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

148 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat